SCHEDULE 13G/A: Anson Funds Discloses 2.1% Stake in Ensysce Biosciences
Beneficial Ownership Report
Anson Funds Management LP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 2.1% in Ensysce Biosciences, Inc. as of December 31, 2024.
Summary
- Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo, and Mr. Moez Kassam collectively reported beneficial ownership of 411,681 shares of Ensysce Biosciences, Inc. Common Stock.
- This ownership represents 2.1% of the outstanding Common Stock of Ensysce Biosciences, Inc.
- The percentage is calculated based on 19,574,014 shares of Common Stock issued and outstanding, as reported in Ensysce Biosciences' Quarterly Report on Form 10-Q filed on November 12, 2024.
- The shares are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook.
Future Outlook
This document is a beneficial ownership report and does not contain any forward-looking statements or guidance regarding Ensysce Biosciences, Inc.'s operations or financial performance.
Industry Context
This filing is a standard disclosure of beneficial ownership by an investment firm, indicating a passive investment stake in Ensysce Biosciences, Inc. It does not provide insights into broader industry trends or competitive dynamics beyond the investment firm's portfolio allocation.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant ownership stakes, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 2024-11-12 | Date Ensysce Biosciences' Quarterly Report on Form 10-Q was filed, reporting 19,574,014 shares of Common Stock outstanding. |
| 2024-12-31 | Date of event which requires the filing of this statement (reporting period end date). |
| 2025-02-14 | Filing date of the Schedule 13G Amendment No. 1. |
Keywords
Ensysce Biosciences, Anson Funds, Schedule 13G, Beneficial Ownership, SEC Filing, Common Stock, Investment Management
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.